- Home
- NTRA
NTRA
Natera Inc.
as 01-21-2025 4:00pm EST
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 22.1B | IPO Year: | 2015 |
| Target Price: | $160.63 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $62.96 - $183.00 | Next Earning Date: | 02-26-2025 |
| Revenue: | $1,531,955,000 | Revenue Growth: | 54.94% |
| Revenue Growth (this year): | 54.35% | Revenue Growth (next year): | 10.17% |
Stock Insider Trading Activity of Natera Inc. (NTRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RABINOWITZ DANIEL | NTRA | SEC. AND CHIEF LEGAL OFFICER | Jan 8 '25 | Sell | $175.30 | 6,223 | $1,090,901.23 | 199,804 | |
| Sheena Jonathan | NTRA | Director | Jan 2 '25 | Sell | $159.70 | 5,700 | $909,125.62 | 255,842 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Dec 20 '24 | Sell | $158.62 | 2,428 | $387,511.41 | 119,420 | |
| Fesko John | NTRA | PRESIDENT, CHIEF BUS. OFFICER | Dec 20 '24 | Sell | $158.78 | 669 | $106,773.49 | 114,142 | |
| Sheena Jonathan | NTRA | Director | Dec 18 '24 | Sell | $167.10 | 5,700 | $953,337.28 | 255,842 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Dec 13 '24 | Sell | $166.45 | 160,000 | $26,518,749.54 | 2,394,480 | |
| Chapman Rowan E | NTRA | Director | Dec 10 '24 | Sell | $170.24 | 1,767 | $300,808.25 | 6,202 | |
| Moshkevich Solomon | NTRA | PRESIDENT, CLINICALDIAGNOSTICS | Dec 9 '24 | Sell | $166.59 | 4,858 | $809,312.19 | 119,420 | |
| BOTHA ROELOF | NTRA | Director | Dec 2 '24 | Sell | $168.70 | 87,473 | $14,793,563.23 | 1,276,177 | |
| Rabinowitz Matthew | NTRA | EXECUTIVE CHAIRMAN | Nov 25 '24 | Sell | $166.63 | 4,000 | $665,375.96 | 2,394,480 |
Latest Natera Inc. News
NTRA Breaking Stock News: Dive into NTRA Ticker-Specific Updates for Smart Investing
Business Wire
5 days ago
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
Investor's Business Daily
5 days ago
Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?'
Business Wire
7 days ago
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
Business Wire
9 days ago
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
Motley Fool
13 days ago
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Business Wire
15 days ago
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Investor's Business Daily
18 days ago
Six IBD 50 Stocks Bear Gifts Even As Santa Claus Rally Fizzles
Simply Wall St.
19 days ago
High Growth Tech Stocks To Watch In January 2025
Compare NTRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NTRA Natera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.